

MAKE THE MOVE

HOLOGIC®

Tackling the backlog for Women's Services – The outpatient solution!

The positive impact of moving minimally invasive surgical treatment for **AUB** and **HMB** to the outpatient department.

The scale of the condition:

12% of all gynaecology referrals are for Menstrual Disorders¹

30,000

surgical treatments

are performed annually in the UK for abnormal uterine bleeding (AUB)²



1 in 5 women

suffer with heavy menstrual bleeding (HMB)

that's **3.8 million women** in the UK^{2,3,4}



What causes AUB/HMB?

There are many known causes of HMB in women, however in the majority of cases no cause is identified. Individualised treatment options are dependent on their ongoing fertility requirements, treatment efficacy and risks, social impact associated with post-procedure recovery and, of course, the patient's choice^{1,5}

What are the surgical treatment options?¹

1st line surgical treatments

Endometrial Ablation (NovaSure®)

Hysteroscopic Tissue Removal (MyoSure®)

Minimally invasive surgery:

NovaSure:
average treatment time - 90 seconds⁶

MyoSure:
average treatment time - 2-5 mins⁷

Can be performed in outpatients
Post procedure recovery: Majority immediate discharge. Up to 1 hour (if required) **NO OVERNIGHT STAY**⁸

2nd line surgical treatment:

Hysterectomy

Major surgery:

Average treatment time - 60-90 mins
Post procedure recovery - 1-4 days⁹
OVERNIGHT STAY

Offering NovaSure & MyoSure in OUTPATIENTS will:



Save £1,000+ per procedure cost*



Enable reallocation of theatre sessions



Reduce waiting lists



Improve patient experience, less time in hospital, faster recovery, less risks



CLICK TO WATCH CASE STUDY

on how East Suffolk and North Essex NHS Foundation Trust have benefited from developing their outpatient gynae services

MyoSure®
Tissue Removal Device

[Click here to find out more](#)

NovaSure®
Endometrial Ablation

[Click here to find out more](#)

For more information and resources visit www.gynsurgicalsolutions.co.uk or contact us at ukgynsurgical@hologic.com

Offering a SEE & TREAT Outpatient Pathway: 3 appointments into 1

Current pathway



Proposed pathway



What do the NICE guidelines recommend?¹

'Women with suspected submucosal fibroids, polyps or endometrial pathology' is published in [Chapter 1.3, Page 6](#)

- Offer **outpatient hysteroscopy to women with HMB** if their history suggests submucosal fibroids, polyps or endometrial pathology
- Ensure that hysteroscopy services are organised to **enable progression to 'see-and-treat' hysteroscopy** in a single setting if feasible

HOLOGIC are market leaders, offering a range of products to support Outpatient Hysteroscopy Service Development

Contact us at ukgynsurgical@hologic.com to request business case tools, cost models and example protocols to support your service development



References:

1. National Institute for Health and Care Excellence [Internet]. Guideline on Heavy menstrual bleeding: assessment and management (NG88) 2018. Available at: <https://www.nice.org.uk/guidance/ng88/resources/heavy-menstrual-bleeding-assessment-and-management-pdf-1837701412549> [nice.org.uk] Last accessed 1st June 2021. 2. Royal College of Obstetricians & Gynaecologists [Internet]. National Heavy Menstrual Bleeding Audit, July 2014. Available at: <https://www.rcog.org.uk/en/guidelines-research-services/audit-quality-improvement/completed-projects/national-hmb-audit/> [rcog.org.uk] Last accessed 1st June 2021. 3. National Health Service [Internet]. Periods and fertility in the menstrual cycle (2019). Available at: <https://www.nhs.uk/conditions/periods/fertility-in-the-menstrual-cycle/> [nhs.uk] Last accessed 1st June 2021. 4. Office for National Statistics [Internet]. Estimates of the population for the UK, England and Wales, Scotland and Northern Ireland, Mid-2016 datasets. Available at: <https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalescotlandandnorthernireland> [ons.gov.uk] Last accessed Feb 2021. 5. Patient [Internet]. Heavy Periods. Available at <https://patient.info/womens-health/periods-and-period-problems/heavy-periods-menorrhagia> Last accessed 8th June 2021. 6. Cooper J, Gimpelson R, Laberge P, et al. A randomized, multicenter trial of safety and efficacy of the NovaSure System in the treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 2002; 9(4):418-28. 7. Rubino RJ, Lukes AS. Twelve-month outcomes for patients undergoing hysteroscopic morcellation of uterine polyps and myomas in an office or ambulatory surgical center. J Minim Invasive Gynceol. 2015; 22(2):285-90. 8. Ajmi A, Das S. Outpatient endometrial ablation: audit of outcomes and patient satisfaction. J Obstet Gynaecol. 2000; 40(8): 1145-1147. 9. National Health Service [Internet]. Recovery – Hysterectomy (2019) Available at <https://www.nhs.uk/conditions/hysterectomy/recovery/> Last accessed 8th June 2021.

*DISCLAIMER: Hologic Ltd has used reasonable efforts to provide accurate costing advice, but this advice should not be construed as providing clinical advice, dictating reimbursement policy or substituting for the judgment of a Practitioner. It is always the provider's responsibility to determine and submit appropriate codes, charges and modifiers for services that are rendered. Provider is responsible for verifying reimbursement coverage. Hologic Ltd assumes no responsibility for the timeliness, accuracy and completeness of the information contained herein. Since reimbursement policy and regulations change frequently, it is recommended that providers consult with the relevant coding department regarding reimbursement coverage. Hologic UK has based treatment/hospitalisation times on the reference indicated and customer experience. This is a general information tool for medical professionals and is not a complete representation of the product(s)' Instruction for Use (IFU) or Package Insert, and it is the medical professionals' responsibility to read and follow the IFU or Package Insert. The information provided may suggest a particular technique or protocol however it is the sole responsibility of the medical professional to determine which technique or protocol is appropriate. At all times, clinicians remain responsible for utilizing sound patient evaluation and selection practices, and for complying with all applicable rules and regulations regarding accreditation, anesthesia, reimbursement, and all other aspects of in-office procedures. In no event shall Hologic® be liable for damages of any kind resulting from your use of the information presented.

GYN Surgical Solutions | gynsurgicalsolutions.co.uk | ukgynsurgical@hologic.com

SS-01036-EUR-EN Rev 002 © 2021 Hologic, Inc. All rights reserved. Hologic, The Science of Sure, MyoSure, NovaSure and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other trademarks are the property of their respective owners. This information is intended for medical professionals and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, podcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your Hologic representative or write to euinfo@hologic.com.